InvestorsHub Logo
Followers 29
Posts 940
Boards Moderated 0
Alias Born 03/10/2014

Re: None

Thursday, 05/28/2015 9:25:19 AM

Thursday, May 28, 2015 9:25:19 AM

Post# of 130502
$AMBS$. Look for more major announcements right after the r/s!

[quote"The core fundamentals of Amarantus have never been stronger, with the upcoming initiation of our Phase 2b clinical study of our lead product candidate, eltoprazine, in Parkinson's disease levodopa-induced dyskinesia and the pending strategic transaction in our diagnostics division. In addition, we believe the potential addition of the clinical-stage orphan candidate ESS, as part of the potential acquisition of Cutanogen Corporation from Lonza, will complement our orphan preclinical MANF programs, while adding a second clinical-stage therapeutic program to bolster our pipeline.
][/quote]

Does anyone actually believe that the deal with Lonza won't go through? With all the money that AMBS has invested so far, I can only speculate that it is actually payments to complete the deal, and not necessarily payments to "keep the option open". Seems to me that Lonza continues to get the accolades of bringing ESS to fruition and keeping employees employed...while AMBS is waiting for the phase 2 to be completed along with the R/S so hey can make the announcement that the deal is completed!
Why else would they get involved in settling lawsuits that they were not involved in?

In My Own Personal Opinion Of Course!

In My Own Personal Opinion Of Course!
Long ANAS!